Legend Biotech Corp (LEGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Legend Biotech Corp (LEGN) has a cash flow conversion efficiency ratio of -0.088x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-85.35 Million) by net assets ($967.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LEGN equity financing ratio to measure how much of total assets are equity-financed.
Legend Biotech Corp - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Legend Biotech Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Legend Biotech Corp to evaluate the quality of earnings relative to operating cash generation.
Legend Biotech Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Legend Biotech Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Schibsted ASA A
OL:SCHA
|
0.011x |
|
CRISIL Limited
NSE:CRISIL
|
0.073x |
|
Pacific Securities Co Ltd
SHG:601099
|
0.071x |
|
Qingdao Huicheng Environmental Co Ltd
SHE:300779
|
-0.010x |
|
KPJ Healthcare Bhd
KLSE:5878
|
0.124x |
|
Wockhardt Limited
NSE:WOCKPHARMA
|
-0.005x |
|
Kirloskar Oil Engines Limited
NSE:KIRLOSENG
|
0.097x |
|
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
|
0.083x |
Annual Cash Flow Conversion Efficiency for Legend Biotech Corp (2017–2025)
The table below shows the annual cash flow conversion efficiency of Legend Biotech Corp from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Legend Biotech Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.00 Billion | $-100.47 Million | -0.100x | +27.57% |
| 2024-12-31 | $1.04 Billion | $-144.03 Million | -0.138x | +55.96% |
| 2023-12-31 | $1.25 Billion | $-393.28 Million | -0.314x | -16.22% |
| 2022-12-31 | $744.31 Million | $-201.28 Million | -0.270x | -4.37% |
| 2021-12-31 | $765.94 Million | $-198.47 Million | -0.259x | +30.31% |
| 2020-12-31 | $599.82 Million | $-223.00 Million | -0.372x | -154.99% |
| 2019-12-31 | $-122.87 Million | $-83.06 Million | 0.676x | -98.10% |
| 2018-12-31 | $8.65 Million | $307.68 Million | 35.574x | +18315.35% |
| 2017-12-31 | $12.17 Million | $-2.38 Million | -0.195x | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more